Argenx
ARGX
#405
Rank
NZ$108.40 B
Marketcap
NZ$1,743
Share price
0.83%
Change (1 day)
45.52%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): NZ$27.23

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$26.71. In 2025 the company made an earnings per share (EPS) of NZ$35.62 an increase over its 2024 EPS that were of NZ$23.52.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$27.23-23.56%
2025NZ$35.6251.44%
2024NZ$23.52-369.77%
2023NZ-$8.72-60.46%
2022NZ-$22.0563.33%
2021NZ-$13.50-40.37%
2020NZ-$22.64183.47%
2019NZ-$7.99123.09%
2018NZ-$3.5854.93%
2017NZ-$2.3114.07%
2016NZ-$2.0313.05%
2015NZ-$1.79-36.34%
2014NZ-$2.81209.04%
2013NZ-$0.91-33.99%
2012NZ-$1.38185.59%
2011NZ-$0.48